Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On August 27, 2026, Dr. Lal Path Labs, through its wholly owned subsidiary Dr. Lal Ventures Private Limited, completed the subscription of a 30% stake in Neuome Technologies Private Limited for ₹35,000,000. This transaction made Neuome Technologies an associate company.
On September 3, 2026, promoter Amit Aggarwal acquired 1,500 shares via ESOP exercise at ₹1,425.715 per share and subsequently sold the same number of shares on the NSE market. Separately, promoter Jai Prakash Meena purchased 2,000 shares through an ESOP exercise at an effective price of ₹1,087.47 per share, while the Dr. Lal PathLabs Employee Welfare Trust sold 5,700 shares acquired under various ESOP exercises.
As of September 18, 2026, Dr. Lal Path Labs has shown the following returns: a 15% return over the last year, a 41% return over the last six months, and a 26% return year-to-date. The return since the start of trading is 24%.
As of September 18, 2026, the daily trend for Dr. Lal Path Labs is indicated as bullish by the Supertrend indicator at 1793.04. Key technical indicators show a closing price of ₹1896.9, with the 50-day Simple Moving Average (SMA) at ₹1864.3 and the 200-day SMA at ₹1573.91. The stock is trading near its nearest support level of ₹1894.77.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹797.70 crore | ₹702.70 crore | ₹659.80 crore | ₹730.60 crore | ₹669.80 crore |
| Finance Costs | ₹6.30 crore | ₹6.10 crore | PEAK₹7.20 crore | ₹4.80 crore | ₹4.70 crore |
| Expenses | PEAK₹600.90 crore | ₹566.60 crore | ₹529.80 crore | ₹551.80 crore | ₹516.80 crore |
| Profit Before Tax | PEAK₹228.70 crore | ₹160.10 crore | ₹124.30 crore | ₹203.60 crore | ₹181.10 crore |
| Tax Expense | PEAK₹58.20 crore | ₹27.90 crore | ₹32.90 crore | ₹51.40 crore | ₹47.10 crore |
| Profit Loss For Period | PEAK₹170.50 crore | ₹132.20 crore | ₹91.40 crore | ₹152.20 crore | ₹134 crore |
Exchange disclosures and regulatory announcements for Dr. Lal Path Labs.
Dr. Lal PathLabs Limited published newspaper advertisements on September 4, 2026, regarding unclaimed equity shares (Interim Dividend FY 2019-20) due for transfer to the Investor Education and Protection Fund (IEPF) under Section 124(6) of the Companies Act, 2013. Individual notices were also sent to concerned shareholders.
On September 3, 2026, Dr. Lal Pathlabs Limited disclosed changes in shareholding for its promoters and related entities under Regulation 7(2). Promoter Amit Aggarwal acquired 1,500 shares via ESOP exercise at INR 1,425.715 per share on September 2, 2026, and subsequently sold the same 1,500 shares via NSE market sale between September 2 and September 3, 2026. Concurrently, promoter Jai Prakash Meena purchased 2,000 shares through an ESOP exercise at an effective price of INR 1,087.47 per share, while the Dr. Lal PathLabs Employee Welfare Trust sold 5,700 shares transferred under various ESOP exercise prices ranging from INR 5 to INR 1,425.715.
Dr. Lal PathLabs Limited, through its wholly owned subsidiary Dr. Lal Ventures Private Limited, completed the subscription of a 30% stake in Neuome Technologies Private Limited on August 27, 2026, making Neuome an associate company.
On August 27, 2026, Dr. Lal Ventures Private Limited, a wholly owned subsidiary of Dr. Lal Path Labs Ltd., completed the subscription for a 30% stake in Neuome Technologies Private Limited for INR 35,000,000. This transaction, which followed Board approval announced on July 24, 2026, resulted in Neuome becoming an associate of the Company.
Dr. Lal Path Labs Ltd. announced that its wholly owned subsidiary, Dr. Lal Ventures Private Limited, completed the subscription of a 30% stake in Neuome Technologies Private Limited on August 27, 2026, for INR 35,000,000. As a result, Neuome has become an associate of the company.
On August 18, 2026, designated person Abhishek Maini acquired 500 equity shares of Dr. Lal PathLabs Limited at INR 965.025 per share under the company's ESOP plan, for a total value of INR 482,515. The next day, August 19, 2026, he sold those 500 shares on the NSE for INR 943,000 via a market sale, resulting in zero post-transaction shareholding. The company was informed of both transactions on August 21, 2026, and filed the disclosure under Regulation 7(2) on August 25, 2026.
On August 19, 2026, Designated Person Amit Aggarwal sold 2,050 equity shares of Dr. Lal PathLabs Limited on the NSE for INR 3,865,357, reducing his holding to zero. Concurrently, on August 24, 2026, the Dr. Lal PathLabs Employee Welfare Trust disposed of 31,300 shares via ESOP transfer at effective exercise prices ranging from INR 1,087.47 to INR 1,452.195 per share, decreasing its stake by 31,300 shares to 709,986 shares.
On August 14, 2026, Sanjay Kulshreshtha, a designated person at Dr. Lal Pathlabs Limited, acquired 1,372 equity shares via ESOP exercise at an effective price of INR 5 per share, resulting in a total transaction value of INR 6,860. This acquisition increased his holding from 3,128 to 4,500 shares, with the post-transaction percentage remaining below 1%. The company disclosed this change on August 20, 2026, confirming the transaction value did not exceed limits under SEBI (Prohibition of Insider Trading) Regulations, 2015.
Recent market and company developments associated with Dr. Lal Path Labs.
MarketSmith India reveals its top stock recommendations for today, 16 September. Get expert insights into the best-performing stocks to guide your investment decisions.
Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage
Market expert Raja Venkatraman shares his top stock picks for 28 July. Here’s his technical outlook and trade strategy.
Dr Lal PathLabs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomura, Nuvama and JM Financial raised target prices, citing robust growth outlook, network expansion and improving margins, with continued momentum expected from diagnostics demand and strategic investments.
Market strategy: Both TCS and SBI Life have been assigned a weight of 150 basis points (bps) in the brokerage’s model portfolio. The brokerage, however, clarified that TCS's inclusion in the model portfolio should not be interpreted as a broader endorsement of the IT services sector.
Comprehensive Section Breakdown for Dr. Lal Path Labs
Dr. Lal PathLabs reported higher revenue and net profit for the first quarter of fiscal 2026-27 compared to the same period last year. Operating expenses grew more slowly than sales, supporting a rise in pre-tax earnings. However, basic earnings per share fell significantly because the number of shares outstanding increased substantially over the past year.
Revenue from operations reached ₹797.70 crore for the quarter ended 30 June 2026, up 19.1% from ₹669.80 crore a year earlier. Sequentially, revenue rose 13.5% from ₹702.70 crore in the preceding quarter. This marks the highest quarterly revenue observed, exceeding the previous peak of ₹730.60 crore in the second quarter of the prior fiscal year.
Total expenses increased 16.3% year-on-year to ₹600.90 crore, growing at a slower pace than revenue. As a percentage of revenue from operations, total expenses declined to 75.3% from 77.2% in the prior-year quarter. This shift contributed to a 26.3% year-on-year increase in profit before tax to ₹228.70 crore. Finance costs were ₹6.30 crore, up from ₹4.70 crore a year ago but remaining a small portion of overall expenses. The effective tax rate was 25.5%, down slightly from 26.0% in the same quarter last year. Net profit for the period rose 27.2% to ₹170.50 crore.
Basic earnings per share for the quarter was ₹10.15, down 36.1% from ₹15.88 in the first quarter of the previous fiscal year. This decline occurred even though net profit increased, indicating that the number of shares outstanding has grown substantially. The reported EPS figures for the intervening quarters also reflect variations consistent with a changed share base.
The quarter delivered higher revenue and net profit, with expenses growing more slowly than sales. The primary offset to headline profit growth is a lower basic earnings per share, driven by a larger number of shares outstanding rather than weaker operating results. Investors evaluating the company's earnings should account for the impact of the expanded share count alongside the underlying profit expansion.
Strategic Vision: Provider of diagnostic and related healthcare services.
Category: B2B Services
Offers pathology services, operates a blood bank, and provides diagnostic testing through a network of clinical laboratories, patient service centers, and pick-up points.
Core Thesis: To be a market leader by providing accessible, affordable, timely, and quality healthcare diagnostics through insights and cutting-edge technology.
• Network Expansion: The company has expanded its network across North, East, South, and West regions, and commissioned a Regional Reference Lab in Kolkata. • Quality Accreditation: Achieved NABL accreditation, ISO 9001:2000 certification, and International Accreditation from CAP for its facilities. • Technological Integration: Utilizes cutting-edge technology to deliver diagnostic services.
• Widespread domestic network of clinical laboratories, patient service centers, and pick-up points.
• International operations in multiple countries.
• Logistics strength supported by a network of satellite labs, staff, and doctors.
• NABL-accredited laboratories.